Efficacies of S-nitrosoglutathione (GSNO) and GSNO reductase inhibitor in SARS-CoV-2 spike protein induced acute lung disease in mice
Judong Kim, Fei Qiao, Avtar K. Singh, Jeseong Won, Inderjit Singh · 2023
Read Efficacies of S-nitrosoglutathione (GSNO) and GSNO reductase inhibitor in SARS-CoV-2 spike protein induced acute lung disease in mice by Judong Kim, Fei Qiao, Avtar K. Singh, Jeseong Won, Inderjit Singh (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10748393.txt.
Description
Judong Kim and colleagues tested in 2023 two treatments for acute lung disease in mice caused by the SARS-CoV-2 spike protein. The virus can drive lung inflammation, vessel harm, and clotting at once, and no drug yet targets all three. The candidate drugs raise or protect a compound called GSNO, which acts on many pathways.
Mice given the spike protein part by nose developed fever, weight loss, lung inflammation, leaky vessels, and clotting signs, much like severe patients. Male mice fared worse than females. Giving GSNO, or blocking the enzyme that breaks it down, protected mice of both sexes across the inflammation, vessel, and clotting measures. The authors back more study of this route.
Catalog record
| CREATOR | Judong Kim, Fei Qiao, Avtar K. Singh, Jeseong Won, Inderjit Singh |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |